US-20260124264-A1 - ANTI-INFLAMMATORY COMPOSITION

Abstract

A composition having a non-polar fraction obtained from at least one fermented plant material is provided. The at least one plant material has been subjected to a lactic acid fermentation.

Inventors

• Jens Hoffner Legarth

Assignees

• FERMENTATIONEXPERTS A/S

Dates

Publication Date

20260507

Application Date

20251104

Priority Date

20190406

Claims (10)

1. 1 - 15 . (canceled)
2. 16 . A method for suppressing one or more of interleukin-12, in a mammal, by administering a composition to the mammal comprising a non-polar fraction obtained from at least one fermented plant material, wherein the at least one plant material is selected from at least one proteinaceous plant material, wherein the proteinaceous plant material is selected from at least one of Brassica spp., seaweed, algae, sunflower, palm, soya, field beans, Lupins, or a combination thereof, and wherein the at least one plant material has been subjected to a lactic acid fermentation for a period of 1-14 days, or for seaweed or algae for an extended period of an additional 10-15 days.
3. 17 . The method according to claim 16 , wherein the non-polar fraction comprises one or more fatty acid compounds.
4. 18 . The method according to claim 16 , wherein the non-polar fraction comprises one or more modified fatty acid compounds.
5. 19 . The method according to claim 16 , wherein the non-polar fraction comprises one or more fatty acid compounds or modified fatty acid compounds selected from a C18-fatty acid compound, a modified C18-fatty acid compound, a linolenic acid compound, or a modified linolenic acid compound.
6. 20 . The method according to claim 16 , wherein the composition is an isolated composition separated from the at least one plant material.
7. 21 . The method according to claim 16 , wherein the lactic acid fermentation involves at least one lactic acid bacteria.
8. 22 . The method according to claim 16 , wherein a fibrous material of the at least one plant material has been removed, or substantially removed, from the composition.
9. 23 . The method according to claim 16 , wherein the plant material is a combination of rape species and seaweed.
10. 24 . The method according to claim 23 , wherein the plant material comprises at least 10% (w/w) rape species and at most 90% seaweed.

Description

TECHNICAL FIELD OF THE INVENTION The present invention relates to a composition, obtained from a fermented plant material, having anti-inflammatory activity and capable of suppressing interleukin-12, interleukin-1β, and/or interleukin-6 activity; and/or suppressing of tumor necrosis factor alpha (TNF-alpha or TNF-α) activity; and/or upregulating interleukin-10, interleukin-1Rα, interleukin-4, interleukin-11, interleukin-13; or transforming growth factor beta (TGF-β); by administration of the composition to a mammal, which composition may be used in the preparation of an anti-inflammatory substance for the treatment, alleviation or prophylaxis of a variety of disorders, including the treatment of pathological conditions associated with inflammation. BACKGROUND OF THE INVENTION Herbal medicines have always been used to fight diseases and infections in humans and animals, and plants has shown to comprise many constituents having positive nutritional and pharmacological effects in the human and animal organism. Despite the long-term knowledge and search for providing products and isolated active ingredients from plants, researchers seldom succeed because of the complexity and interplay between the individual components of the plants. Examples of potent extracts from plants that are well integrated in modern medical treatment can be found in drugs such as Morphine for treatment of severe pain, Digitalis for treatment of heart disease, Taxole for cancer treatment. Furthermore, reaction products from plants that have been chemically or microbial treated have shown to be very interesting. However, predicting the interesting reaction products and how to provide the relevant reaction product is very difficult or even impossible. Often it is also difficult to predict that one reaction product may be responsible for the activity of e.g. a fermented plant material, as the fermented plant material is a complex mixture of an enormous number of different compounds where some products have pharmacological activity by itself and other only possess the pharmacological activity when in the complex mixture. Mammals, like humans and animals, subjected to an inflammation express an increased activity in one or more cytokines. Two of the most common cytokins that are followed when dealing with an inflammation may be selected from the group consisting of interleukin-12, interleukin-1β, interleukin-6, tumor necrosis factor alpha (TNF-alpha or TNF-α), interleukin-10, interleukin-1Ra, interleukin-4, interleukin-11, interleukin-13; and transforming growth factor beta (TGF-β). In particular, interleukin 10, interleukin-12 and tumor necrosis factor alpha (TNF-alpha or TNF-α) may be followed. Cytokines are small, secreted polypeptides from higher eukaryotes which are responsible for intercellular signal transduction and which affect the growth, division and functions of other cells. They are potent, pleiotropic polypeptides that, e.g. via corresponding receptors, act as local or systemic intercellular regulatory factors, and therefore play crucial roles in many biologic processes, such as immunity, inflammation, and hematopoiesis. Cytokines are produced by diverse cell types including fibroblasts, endothelial cells, epithelial cells, macrophages/monocytes, and lymphocytes. Current anti-inflammatory drugs are designed to act in an indirect manner, by blocking the action of e.g. interleukin-12, interleukin-1β, and/or interleukin-6 activity; and/or suppression of tumor necrosis factor alpha (TNF-alpha or TNF-α) activityby binding to it and hereby prevents it from signaling the receptors for TNF-α on the surface of cells. This type of blocking has some serious side effects, of which some is infections such as tuberculosis, sepsis and fungal infections and possible increased cancer incidence, and an increased cytokine activity is still provided. Hence, there is a need in the industry for new products and compounds for the efficient treatment, alleviation and/or prophylaxis of an inflammatory disease or disorder in a mammal. SUMMARY OF THE INVENTION Thus, an object of the present invention relates to a composition obtained from a fermented plant material, having anti-inflammatory activity and capable of: suppressing interleukin-12, interleukin-1β, and/or interleukin-6 activity; and/orsuppressing of tumor necrosis factor alpha (TNF-alpha or TNF-α) activity; and/orupregulating interleukin-10, interleukin-1Ra, interleukin-4, interleukin-11, interleukin-13; or transforming growth factor beta (TGF-β). In particular, it is an object of the present invention to provide a new product and a new compound for the efficient treatment, alleviation and/or prophylaxis of an inflammatory disease or disorder in a mammal, and which product or compound solves the above-mentioned problems of the prior art with activity and side effects. Thus, one aspect of the invention relates to a composition comprising a non-polar fraction obtained from at least one fermented p